2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Brisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerBristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and Share XBrisk trade in risky three-drug ‘bet’ option after BMS/Celgene mergerhttps://pharmaphorum.com/news/celgene-shareholders/
$74bn BMS/Celgene merger finally cleared by competition regulatorsBristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 Share X$74bn BMS/Celgene merger finally cleared by competition regulatorshttps://pharmaphorum.com/news/74bn-bms-celgene-merger-finally-cleared-by-competition-regulators/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Celgene strikes $1.5bn cell therapy deal with ImmaticsCelgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws Share XCelgene strikes $1.5bn cell therapy deal with Immaticshttps://pharmaphorum.com/news/celgene-strikes-1-5bn-cell-therapy-deal-with-immatics/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
